Pfizer Gross Profit 2010-2024 | PFE
Pfizer annual/quarterly gross profit history and growth rate from 2010 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Pfizer gross profit for the quarter ending December 31, 2024 was $11.854B, a 69.17% increase year-over-year.
- Pfizer gross profit for the twelve months ending December 31, 2024 was $45.776B, a 32.3% increase year-over-year.
- Pfizer annual gross profit for 2024 was $45.776B, a 32.3% increase from 2023.
- Pfizer annual gross profit for 2023 was $34.599B, a 48.23% decline from 2022.
- Pfizer annual gross profit for 2022 was $66.831B, a 32.43% increase from 2021.
Pfizer Annual Gross Profit
(Millions of US $) |
| 2024 |
$45,776 |
| 2023 |
$34,599 |
| 2022 |
$66,831 |
| 2021 |
$50,467 |
| 2020 |
$33,167 |
| 2019 |
$32,851 |
| 2018 |
$31,838 |
| 2017 |
$41,318 |
| 2016 |
$40,502 |
| 2015 |
$39,203 |
| 2014 |
$40,028 |
| 2013 |
$41,998 |
| 2012 |
$44,836 |
| 2011 |
$48,535 |
| 2010 |
$50,377 |
| 2009 |
$40,810 |
Pfizer Quarterly Gross Profit
(Millions of US $) |
| 2024-12-31 |
$11,854 |
| 2024-09-30 |
$12,439 |
| 2024-06-30 |
$9,983 |
| 2024-03-31 |
$11,500 |
| 2023-12-31 |
$7,007 |
| 2023-09-30 |
$4,222 |
| 2023-06-30 |
$9,770 |
| 2023-03-31 |
$13,600 |
| 2022-12-31 |
$15,485 |
| 2022-09-30 |
$16,575 |
| 2022-06-30 |
$19,094 |
| 2022-03-31 |
$15,677 |
| 2021-12-31 |
$14,102 |
| 2021-09-30 |
$14,103 |
| 2021-06-30 |
$11,903 |
| 2021-03-31 |
$10,359 |
| 2020-12-31 |
$8,716 |
| 2020-09-30 |
$8,270 |
| 2020-06-30 |
$8,038 |
| 2020-03-31 |
$8,143 |
| 2019-12-31 |
$1,400 |
| 2019-09-30 |
$10,078 |
| 2019-06-30 |
$10,688 |
| 2019-03-31 |
$10,685 |
| 2018-12-31 |
$341 |
| 2018-09-30 |
$10,604 |
| 2018-06-30 |
$10,550 |
| 2018-03-31 |
$10,343 |
| 2017-12-31 |
$10,447 |
| 2017-09-30 |
$10,324 |
| 2017-06-30 |
$10,236 |
| 2017-03-31 |
$10,311 |
| 2016-12-31 |
$10,415 |
| 2016-09-30 |
$9,960 |
| 2016-06-30 |
$9,973 |
| 2016-03-31 |
$10,154 |
| 2015-12-31 |
$10,636 |
| 2015-09-30 |
$9,868 |
| 2015-06-30 |
$9,673 |
| 2015-03-31 |
$9,026 |
| 2014-12-31 |
$10,416 |
| 2014-09-30 |
$9,993 |
| 2014-06-30 |
$10,311 |
| 2014-03-31 |
$9,308 |
| 2013-12-31 |
$10,764 |
| 2013-09-30 |
$10,356 |
| 2013-06-30 |
$10,731 |
| 2013-03-31 |
$10,147 |
| 2012-12-31 |
$10,460 |
| 2012-09-30 |
$10,644 |
| 2012-06-30 |
$11,592 |
| 2012-03-31 |
$12,140 |
| 2011-12-31 |
$9,612 |
| 2011-09-30 |
$13,200 |
| 2011-06-30 |
$12,914 |
| 2011-03-31 |
$12,809 |
| 2010-12-31 |
$12,350 |
| 2010-09-30 |
$12,205 |
| 2010-06-30 |
$13,448 |
| 2010-03-31 |
$12,374 |
| 2009-12-31 |
$12,291 |
| 2009-09-30 |
$9,832 |
| 2009-06-30 |
$9,228 |
| 2009-03-31 |
$9,459 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$151.025B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
